Andrew McQuillan

892 total citations
19 papers, 571 citations indexed

About

Andrew McQuillan is a scholar working on Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine and Internal Medicine. According to data from OpenAlex, Andrew McQuillan has authored 19 papers receiving a total of 571 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pathology and Forensic Medicine, 5 papers in Pulmonary and Respiratory Medicine and 5 papers in Internal Medicine. Recurrent topics in Andrew McQuillan's work include Lymphoma Diagnosis and Treatment (8 papers), Venous Thromboembolism Diagnosis and Management (5 papers) and Lung Cancer Treatments and Mutations (4 papers). Andrew McQuillan is often cited by papers focused on Lymphoma Diagnosis and Treatment (8 papers), Venous Thromboembolism Diagnosis and Management (5 papers) and Lung Cancer Treatments and Mutations (4 papers). Andrew McQuillan collaborates with scholars based in Australia, United Kingdom and Canada. Andrew McQuillan's co-authors include John W. Eikelboom, Daniel J. Quinlan, Ross Baker, Janelle Staton, Graeme J. Hankey, Jim Thom, Qilong Yi, Paul Cherian, J. Harvey Turner and W. B. Macdonald and has published in prestigious journals such as Blood, Annals of Internal Medicine and Stroke.

In The Last Decade

Andrew McQuillan

19 papers receiving 547 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrew McQuillan Australia 10 291 237 136 124 93 19 571
Doyeun Oh South Korea 15 190 0.7× 110 0.5× 63 0.5× 52 0.4× 163 1.8× 29 552
Cristina Falcó Spain 16 116 0.4× 126 0.5× 219 1.6× 39 0.3× 50 0.5× 19 567
Francesca Duca Italy 7 336 1.2× 176 0.7× 528 3.9× 85 0.7× 28 0.3× 9 799
C. M. Schambeck Germany 13 150 0.5× 71 0.3× 233 1.7× 29 0.2× 47 0.5× 26 452
Bahriye Payzın Türkiye 9 56 0.2× 116 0.5× 65 0.5× 66 0.5× 38 0.4× 33 450
Jane M. Benson United States 12 137 0.5× 122 0.5× 425 3.1× 37 0.3× 63 0.7× 20 685
Thomas Dahlman Sweden 8 295 1.0× 258 1.1× 339 2.5× 24 0.2× 35 0.4× 9 644
Jean Chidiac France 11 172 0.6× 152 0.6× 62 0.5× 19 0.2× 63 0.7× 23 371
J Fernández-Llamazares Spain 10 124 0.4× 56 0.2× 56 0.4× 57 0.5× 25 0.3× 27 499
G.-F. von Tempelhoff Germany 9 153 0.5× 99 0.4× 109 0.8× 16 0.1× 50 0.5× 24 366

Countries citing papers authored by Andrew McQuillan

Since Specialization
Citations

This map shows the geographic impact of Andrew McQuillan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew McQuillan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew McQuillan more than expected).

Fields of papers citing papers by Andrew McQuillan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew McQuillan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew McQuillan. The network helps show where Andrew McQuillan may publish in the future.

Co-authorship network of co-authors of Andrew McQuillan

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew McQuillan. A scholar is included among the top collaborators of Andrew McQuillan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew McQuillan. Andrew McQuillan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Minson, Adrian, Nada Hamad, Dipti Talaulikar, et al.. (2023). Death from mantle cell lymphoma limits sequential therapy, particularly after first relapse: Patterns of care and outcomes in a series from Australia and the United Kingdom. British Journal of Haematology. 204(2). 548–554. 3 indexed citations
2.
Erber, Wendy N., Henry Hui, Bradley Augustson, et al.. (2020). Detection of Del(17p) in Hematological Malignancies By Imaging Flow Cytometry. Blood. 136(Supplement 1). 9–10. 5 indexed citations
3.
Hui, Henry, et al.. (2019). “Immuno‐flowFISH” for the Assessment of Cytogenetic Abnormalities in Chronic Lymphocytic Leukemia. Cytometry Part A. 95(5). 521–533. 19 indexed citations
4.
5.
Kesavan, Murali, Andrew McQuillan, W. B. Macdonald, & J. Harvey Turner. (2017). AN INTERNATIONAL COMPARISON OF THE EFFICACY, COST AND MYELOTOXICITY OF FIRST‐LINE THERAPY FOR ADVANCED FOLLICULAR NON‐HODGKIN LYMPHOMA. Hematological Oncology. 35(S2). 366–367. 1 indexed citations
6.
McQuillan, Andrew, W. B. Macdonald, & J. Harvey Turner. (2014). Phase II study of first-line131I-rituximab radioimmunotherapy in follicular non-Hodgkin lymphoma and prognostic18F-fluorodeoxyglucose positron emission tomography. Leukemia & lymphoma. 56(5). 1271–1277. 18 indexed citations
7.
McQuillan, Andrew, W. B. Macdonald, Michael F. Leahy, & J. Harvey Turner. (2011). First-Line Radio-Immunotherapy of Newly Diagnosed, Advanced Follicular Non-Hodgkin Lymphoma with 131I-Rituximab: The INITIAL Study,. Blood. 118(21). 3719–3719. 2 indexed citations
8.
9.
Eikelboom, John W., et al.. (2004). Renal Function, Peak Anti‐Xa Levels and Enoxaparin Dosing. Journal of Pharmacy Practice and Research. 34(1). 14–17. 6 indexed citations
10.
Grigg, AP, John Reynolds, Andrew McQuillan, et al.. (2004). Prognostic features for response and survival in elderly patients withde novoacute myeloid leukemia treated with mitoxantrone and intermediate dose cytarabine. Leukemia & lymphoma. 46(3). 367–375. 9 indexed citations
11.
Quinlan, Daniel J., Andrew McQuillan, & John W. Eikelboom. (2004). Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism. a meta-analysis of randomized, controlled trials. ACC Current Journal Review. 13(5). 13–14. 13 indexed citations
12.
Quinlan, Daniel J., Andrew McQuillan, & John W. Eikelboom. (2004). Low-Molecular-Weight Heparin Compared with Intravenous Unfractionated Heparin for Treatment of Pulmonary Embolism. Annals of Internal Medicine. 140(3). 175–183. 251 indexed citations
13.
McQuillan, Andrew, John W. Eikelboom, & Ross Baker. (2003). Venous thromboembolism in travellers: can we identify those at risk?. PubMed. 14(7). 671–5. 19 indexed citations
14.
McQuillan, Andrew, John W. Eikelboom, & Ross Baker. (2003). Venous thromboembolism in travellers. Blood Coagulation & Fibrinolysis. 14(7). 671–675. 16 indexed citations
15.
Eikelboom, John W., Graeme J. Hankey, Ross Baker, et al.. (2003). C-reactive protein in ischemic stroke and its etiologic subtypes. Journal of Stroke and Cerebrovascular Diseases. 12(2). 74–81. 36 indexed citations
16.
Cherian, Paul, Graeme J. Hankey, John W. Eikelboom, et al.. (2003). Endothelial and Platelet Activation in Acute Ischemic Stroke and Its Etiological Subtypes. Stroke. 34(9). 2132–2137. 146 indexed citations
17.
Crawford, Julie, John W. Eikelboom, & Andrew McQuillan. (2002). Recurrent palmar–plantar erythrodysaesthesia following high‐dose cytarabine treatment for acute lymphoblastic leukemia. European Journal Of Haematology. 69(5-6). 315–317. 9 indexed citations
18.
Cripps, C., et al.. (1999). A Phase I study of ‘Tomudex’ and gemcitabine in advanced cancer. European Journal of Cancer. 35. S289–S289. 1 indexed citations
19.
McQuillan, Andrew, et al.. (1996). Follow-up study of a group of schizophrenic patients and their involvement in religious activities. Schizophrenia Research. 18(2-3). 239–239. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Doyeun Oh Breakdown of academic impact, for papers by Cristina Falcó Breakdown of academic impact, for papers by Francesca Duca Breakdown of academic impact, for papers by C. M. Schambeck Breakdown of academic impact, for papers by Bahriye Payzın Breakdown of academic impact, for papers by Jane M. Benson Breakdown of academic impact, for papers by Thomas Dahlman Breakdown of academic impact, for papers by Jean Chidiac Breakdown of academic impact, for papers by J Fernández-Llamazares Breakdown of academic impact, for papers by G.-F. von Tempelhoff
Rankless by CCL
2026